Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Vijayvel Jayaprakash"'
Autor:
M. Radhakrishna Pillai, Vijayvel Jayaprakash, Shivashankar Parashuram, Sudhakar Babu Katakam, Kannan Ranganathan, Hiran K. Ravindran, Thara Somanathan, Gigi Thomas, Nisha Asok Kumar, Surya Ramachandran, Prathiba R, Rajneesh R. Kumar, Divya Ravindran, Amritha Suresh, Kalavathy K. Elango, Gunaseelan Rajan, Subramanya Iyer, Bindu Dey, Kunnambath Ramdas, Moni Abraham Kuriakose
Clinical appearance of different leukoplakia.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::803659e19ff2d387f407b5ebf38119d7
https://doi.org/10.1158/1940-6207.22534594
https://doi.org/10.1158/1940-6207.22534594
Autor:
M. Radhakrishna Pillai, Vijayvel Jayaprakash, Shivashankar Parashuram, Sudhakar Babu Katakam, Kannan Ranganathan, Hiran K. Ravindran, Thara Somanathan, Gigi Thomas, Nisha Asok Kumar, Surya Ramachandran, Prathiba R, Rajneesh R. Kumar, Divya Ravindran, Amritha Suresh, Kalavathy K. Elango, Gunaseelan Rajan, Subramanya Iyer, Bindu Dey, Kunnambath Ramdas, Moni Abraham Kuriakose
Patient disposition and clinical follow up results.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c870d48b6b797f092b78b879ef00929
https://doi.org/10.1158/1940-6207.22534597.v1
https://doi.org/10.1158/1940-6207.22534597.v1
Autor:
M. Radhakrishna Pillai, Vijayvel Jayaprakash, Shivashankar Parashuram, Sudhakar Babu Katakam, Kannan Ranganathan, Hiran K. Ravindran, Thara Somanathan, Gigi Thomas, Nisha Asok Kumar, Surya Ramachandran, Prathiba R, Rajneesh R. Kumar, Divya Ravindran, Amritha Suresh, Kalavathy K. Elango, Gunaseelan Rajan, Subramanya Iyer, Bindu Dey, Kunnambath Ramdas, Moni Abraham Kuriakose
Supplementary Table ST1: Results of clinical, histological and combined response evaluation Supplementary Table ST2: Results of clinical response only in patients who have 6 month clinical evaluation completed. Supplementary Table ST3: Summary of ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::367c59f7a4815fc1e4dc15740fddda18
https://doi.org/10.1158/1940-6207.22534591
https://doi.org/10.1158/1940-6207.22534591
Autor:
M. Radhakrishna Pillai, Vijayvel Jayaprakash, Shivashankar Parashuram, Sudhakar Babu Katakam, Kannan Ranganathan, Hiran K. Ravindran, Thara Somanathan, Gigi Thomas, Nisha Asok Kumar, Surya Ramachandran, Prathiba R, Rajneesh R. Kumar, Divya Ravindran, Amritha Suresh, Kalavathy K. Elango, Gunaseelan Rajan, Subramanya Iyer, Bindu Dey, Kunnambath Ramdas, Moni Abraham Kuriakose
Oral leukoplakia is a potentially malignant lesion of the oral cavity, for which no effective treatment is available. We investigated the effectiveness of curcumin, a potent inhibitor of NF-κB/COX-2, molecules perturbed in oral carcinogenesis, to tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::400e8abcd7fddfbb9a03b741bc0095ef
https://doi.org/10.1158/1940-6207.c.6547567.v1
https://doi.org/10.1158/1940-6207.c.6547567.v1
Autor:
Makoto Tahara, Yasushi Shimizu, Wing Sum Kenneth Li, Naomi Kiyota, Toshimitsu Endo, Masahiro Goto, Jin Hyoung Kang, Tomoya Yokota, Chia Jui Yen, Vijayvel Jayaprakash, Robert L. Ferris, Ruey-Long Hong, Shunji Takahashi, Maura L. Gillison, Shigemichi Iwae, Nobuhiro Hanai
Publikováno v:
Head & Neck. 42:2852-2862
Background The present study evaluated the 2-year survival of the Asian population in the CheckMate 141 trial. Methods The CheckMate 141 trial included patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
Autor:
Maura L Gillison, George Blumenschein, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin J Harrington, Stefan Kasper, Everett E Vokes, Caroline Even, Francis Worden, Nabil F Saba, Lara Carmen Iglesias Docampo, Robert Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Vijayvel Jayaprakash, Li Wei, Robert L Ferris
In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator’s choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic squamous cell carcinoma of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d8adb6da303b0dd011608467144cda2
https://www.ncbi.nlm.nih.gov/pubmed/35641218
https://www.ncbi.nlm.nih.gov/pubmed/35641218
Autor:
Jérôme Fayette, Vijayvel Jayaprakash, Kevin J. Harrington, Robert L. Ferris, Li Li, Maura L. Gillison, Peter Brossart, Nabil F. Saba, Joël Guigay, Lisa Licitra, Naomi Kiyota, George R. Blumenschein
Publikováno v:
Oral oncology
Objectives: Many patients with squamous cell carcinoma of the head and neck (SCCHN) are ≥65 years old; comorbidities and other age-related factors may affect their ability to tolerate traditional chemotherapy. Nivolumab is the only immunotherapy to
Autor:
Chia-Jui, Yen, Naomi, Kiyota, Nobuhiro, Hanai, Shunji, Takahashi, Tomoya, Yokota, Shigemichi, Iwae, Yasushi, Shimizu, Ruey-Long, Hong, Masahiro, Goto, Jin-Hyoung, Kang, Wing Sum Kenneth, Li, Robert L, Ferris, Maura, Gillison, Toshimitsu, Endo, Vijayvel, Jayaprakash, Makoto, Tahara
Publikováno v:
Head & Neck
Background The present study evaluated the 2‐year survival of the Asian population in the CheckMate 141 trial. Methods The CheckMate 141 trial included patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)
Autor:
Mark Rudinski, Zhao Yang, Vijayvel Jayaprakash, Anu Doraiswamy, Farhad Ravandi, Marjo Hahka-Kemppinen, Marek K. Kania
Publikováno v:
Blood. 138:4438-4438
Background: Isocitrate dehydrogenase (IDH) is a rate-limiting tricarboxylic acid cycle enzyme with 3 isoforms. Mutations in IDH1 and IDH2 result in gain-of-function activity that can result in tumor formation and/or progression and have been associat
Autor:
Paolo Strati, Mark Rudinski, Rathi Pillai, Michał Taszner, Dominik Chraniuk, Caly Chien, Shivani Nanda, Marek K. Kania, Eva González-Barca, Vijayvel Jayaprakash, Marjo Hahka-Kemppinen
Publikováno v:
Blood. 138:2432-2432
Background: Spleen tyrosine kinase (Syk) plays an integral role in B-cell receptor signaling critical in the development and survival of several subtypes of lymphoma. HMPL-523 is a selective, oral Syk inhibitor that has shown strong anti-tumor effica